Grab Holdings Ltd. vs Medpace Holdings Inc — how do they compare? Grab Holdings Ltd. trades at $3.62 (market cap $15.26B), while Medpace Holdings Inc trades at $599.61 (market cap $16.90B). The key difference: Grab Holdings Ltd. and Medpace Holdings Inc are close in size by market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Grab Holdings Ltd. nearer its low. Which is the better fit depends on your goals.
| GRAB | MEDP | |
|---|---|---|
Market Cap | $15.26B | $16.90B |
Sector | Technology | Technology |
52-Week High | $6.45 | $620.59 |
52-Week Low | $3.27 | $393.42 |
Enterprise Value | $10.99B | $16.52B |
Signals from Pluang's Aura AI — not financial advice
GRAB trades at $3.605, down 1.77% today, but maintains a bullish technical trend. The company reported strong Q2 2026 earnings, beating estimates with $0.06 EPS, and raised full-year revenue guidance to 22-23% growth. Positive analyst sentiment includes an average price target of $5.86, implying 58% upside. Fundamentals show improving profitability, with net income turning positive in 2025 at $268 million and margins expanding.
Outlook is positive given earnings momentum and raised guidance, but risks include high valuation multiples, insider selling, and competitive pressures in Southeast Asia. The stock offers growth potential if execution continues, yet investors should weigh valuation against profitability sustainability and market volatility.
MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.
Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.
Trailing returns across standard periods
Latest headlines on both assets
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →